Idenix Focusing On HIV Program, Tyzeka Launch Following Clinical Hold On Hep C Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA decision stems mainly from GI concerns that have dogged valopicitabine development, Idenix said.